Serum matrix metalloproteinase-9 and venous bypass graft occlusion.
Scand J Clin Lab Invest
; 66(1): 7-14, 2006.
Article
in En
| MEDLINE
| ID: mdl-16464782
ABSTRACT
OBJECTIVE:
The primary results after coronary artery bypass grafting are good, but early clinical events as a result of graft occlusion are still a problem. Early occlusions are thought to be due to thrombosis or fibrointimal hyperplasia superimposed by thrombosis, but the etiology of these phenomena is not fully understood. Matrix metalloproteinase-9 has been suggested to have a role in graft occlusion ex vivo. MATERIAL ANDMETHODS:
We investigated whether the level of serum matrix metalloproteinase-9 reflects its proposed role in occlusion of vein grafts. The study population consisted of 30 men with a history of myocardial infarction and 31 men without myocardial infarction who had undergone coronary artery bypass grafting. All the men were asymptomatic.RESULTS:
Among the patients with no previous myocardial infarction, serum matrix metalloproteinase-9 level was significantly higher in those with graft occlusion than in those without occlusion (54.0+/-11.0 microg/L and 41.7+/-10.4 microg/L, respectively, p = 0.006), and it correlated positively with the number of occluded grafts (R = 0.55, p = 0.001). In the patients with myocardial infarction, this effect was not detected.CONCLUSIONS:
Serum matrix metalloproteinase-9 reflected the occurrence of vein graft occlusion in subjects with no previous history of myocardial infarction.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Matrix Metalloproteinase 9
/
Graft Occlusion, Vascular
/
Lipoproteins, LDL
Limits:
Aged
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Scand J Clin Lab Invest
Year:
2006
Document type:
Article
Affiliation country:
Finlandia